Previous close | 6.00 |
Open | 6.00 |
Bid | 1.75 |
Ask | 2.60 |
Strike | 30.00 |
Expiry date | 2024-10-18 |
Day's range | 6.00 - 6.00 |
Contract range | N/A |
Volume | |
Open interest | 8 |
Q4 2024 Roivant Sciences Ltd Earnings Call
Immunovant stock slumped Thursday — reversing a day-earlier jump — after pivoting its focus to what one analyst called "a backup compound."
Immunovant (IMVT) declines 5% on dismal fourth-quarter fiscal 2024 results. The company names IMVT-1402 as its new lead candidate to initiate several studies for autoimmune indications.